Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00945061
Other study ID # CASE11107
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 23, 2008
Est. completion date July 6, 2018

Study information

Verified date August 2020
Source Case Comprehensive Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. It is not yet known whether a single dose of radiation therapy is more effective than implant radiation therapy for 5 days in treating patients with recurrent breast cancer.

PURPOSE: This phase II trial is studying implant radiation therapy to see how well it works compared with radiation therapy during surgery in treating patients with recurrent breast cancer.


Description:

OBJECTIVES:

- To determine the in breast recurrence rate following repeat radiation to the breast. These patients will be followed for a period of five years following completion of radiation to determine these rates.

- To determine the cosmetic outcome resulting from partial breast re-irradiation using different techniques, including both physician and patient rated scales.

- To determine patient satisfaction of partial breast re-irradiation as it pertains to their overall treatment experience, as measured by a questionnaire.

- To determine if there are patient factors illuminated during a discussion of informed consent, which limit a patient's suitability to receive partial breast re-irradiation delivered by a particular technique.

- To evaluate tylectomy wound healing and overall complication rate after partial breast re-irradiation.

- To determine ipsilateral breast tumor recurrence rates and tumor bed recurrence rates.These patients will be followed for a period of five years following completion of the second course of radiation to determine these rates.

OUTLINE: Patients are stratified according to which modality is best suited for the patient. Patients are assigned to 1 of 2 groups.

All patients undergo excisional biopsy or needle localization removal of the tumor. Patients with margins < 2 mm undergo re-excision of the biopsy cavity.

- Group 1: Patients undergo partial breast irradiation delivered as a single intra-operative radiation dose to the tumor bed.

- Group 2: Patients undergo partial breast irradiation delivered by Mammosite® brachytherapy consisting of 10 fractions over 5 days.

Quality of life is assessed at baseline, 1 month after completion of radiotherapy, and then at follow-up visits.

After completion of study treatment, patients are followed up at 1 month, every 3 months for 1 year, and then every 6 months for 5 years.


Recruitment information / eligibility

Status Completed
Enrollment 13
Est. completion date July 6, 2018
Est. primary completion date July 6, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients' recurrences must have histologically confirmed ductal carcinoma in-situ, invasive ductal, medullary, papillary, colloid (mucinous), or tubular histologies.

- Lesion size = 3 cm treated with a tylectomy and whole breast irradiation (with or without tumor bed boost)

- Unifocal breast cancer recurrence

- Negative resection margins with at least a 2 mm margin from invasive and in situ cancer or a negative re-excision

- Hormonal therapy is allowed. If chemotherapy is planned, the radiation is delivered first and chemotherapy must begin no earlier than two weeks following completion of radiation.

- Signed study-specific informed consent prior to study entry.

Exclusion Criteria:

- Patients with distant metastatic disease

- Patients with invasive lobular carcinoma, extensive lobular carcinoma in-situ, extensive ductal carcinoma in-situ (spanning more than 3 cm), or nonepithelial breast malignancies such as lymphoma or sarcoma.

- Patients with multicentric carcinoma (tumors in different quadrants of the breast or tumors separated by at least 4 cm). Palpable or radiographically suspicious contralateral axillary, ipsilateral or contralateral supraclavicular, infraclavicular, or internal mammary lymph nodes unless these are histologically or cytologically confirmed negative.

- Extensive intraductal component (EIC) by the Harvard definition, i.e. 1) more than 25% of the invasive tumor is Ductal carcinoma in situ (DCIS) and DCIS present in adjacent breast tissue. Presence of an EIC increases the chance of local recurrence, and as such, one might not be a candidate for repeat breast conservation.

- Patients with Paget's disease of the nipple.

- Patients with skin involvement.

- Patients with collagen vascular disorders, specifically systemic lupus erythematosis, scleroderma, or dermatomyositis.

- Patients with psychiatric, neurologic, or addictive disorders that would preclude obtaining informed consent.

- Other malignancy, except non-melanomatous skin cancer, < 5 years prior to participation in this study.

- Patients who are pregnant or lactating due to potential fetal exposure to radiation and unknown effects of radiation on lactating females.

- Patients with known BReast CAncer gene (BRCA)1/BRCA 2 mutations.

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
intracavitary balloon brachytherapy
Patients undergo brachytherapy
intraoperative radiation therapy
Patients undergo radiotherapy

Locations

Country Name City State
United States UHHS Chagrin Highlands Medical Center Cleveland Ohio
United States UHHS Westlake Medical Center Cleveland Ohio
United States University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center Cleveland Ohio

Sponsors (1)

Lead Sponsor Collaborator
Case Comprehensive Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Ipsilateral Breast Tumor Recurrence Rates Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast. 1 month after radiation therapy (RT)
Primary Ipsilateral Breast Tumor Recurrence Rates Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast. 3 months after RT
Primary Ipsilateral Breast Tumor Recurrence Rates Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast. 6 months after RT
Primary Ipsilateral Breast Tumor Recurrence Rates Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast. 9 months after RT
Primary Ipsilateral Breast Tumor Recurrence Rates Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast. 12 months after RT
Primary Ipsilateral Breast Tumor Recurrence Rates Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast. 2 years after RT
Primary Ipsilateral Breast Tumor Recurrence Rates Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast. 3 years after RT
Primary Ipsilateral Breast Tumor Recurrence Rates Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast. 4 years after RT
Primary Ipsilateral Breast Tumor Recurrence Rates Percent of participants with Ipsilateral breast tumor recurrence (IBTR). IBTR includes: true recurrence (TR) thought to occur when residual cancer cells grow gradually to detectable size and new primary (NP) thought to be new cancer independently arising in the preserved breast. 5 years after RT
Primary Tumor Bed Recurrence Rates Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision 1 month after RT
Primary Tumor Bed Recurrence Rates Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision 3 month after RT
Primary Tumor Bed Recurrence Rates Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision 6 month after RT
Primary Tumor Bed Recurrence Rates Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision 12 month after RT
Primary Tumor Bed Recurrence Rates Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision 2 years after RT
Primary Tumor Bed Recurrence Rates Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision 3 years after RT
Primary Tumor Bed Recurrence Rates Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision 4 years after RT
Primary Tumor Bed Recurrence Rates Percent of participants with tumor bed recurrence, defined as recurrence in the same quadrant as the surgical excision 5 years after RT
Primary Cosmetic Outcome as Determined by an Established Scale Cosmetic outcome as determined by four-level scale of cosmetic outcome scale, with levels poor, fair, good, and excellent in increasingly positive outcomes.
Excellent: Minimal or no difference in the size or shape of the treated breast Good: Slight difference in the size or shape of the treated breast Fair: Obvious difference in the shape and size of the treated breast Poor: Obvious difference in the shape and size of the treated breast
1 month after RT & Q3mos for one year and at 5 years
Primary Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey
Participants indicate level of satisfaction by answering "my satisfaction about the treatment and results is"
I am totally satisfied with the treatment and results
I am not totally satisfied but would choose the same treatment again.
I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again.
I am dissatisfied with my treatment.
1 month after RT
Primary Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey
Participants indicate level of satisfaction by answering "my satisfaction about the treatment and results is"
I am totally satisfied with the treatment and results
I am not totally satisfied but would choose the same treatment again.
I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again.
I am dissatisfied with my treatment.
3 month after RT
Primary Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey
Participants indicate level of satisfaction by answering "my satisfaction about the treatment and results is"
I am totally satisfied with the treatment and results
I am not totally satisfied but would choose the same treatment again.
I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again.
I am dissatisfied with my treatment.
6 month after RT
Primary Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey
Participants indicate level of satisfaction by answering "my satisfaction about the treatment and results is"
I am totally satisfied with the treatment and results
I am not totally satisfied but would choose the same treatment again.
I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again.
I am dissatisfied with my treatment.
9 month after RT
Primary Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey
Participants indicate level of satisfaction by answering "my satisfaction about the treatment and results is"
I am totally satisfied with the treatment and results
I am not totally satisfied but would choose the same treatment again.
I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again.
I am dissatisfied with my treatment.
12 month after RT
Primary Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey
Participants indicate level of satisfaction by answering "my satisfaction about the treatment and results is"
I am totally satisfied with the treatment and results
I am not totally satisfied but would choose the same treatment again.
I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again.
I am dissatisfied with my treatment.
2 years after RT
Primary Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey
Participants indicate level of satisfaction by answering "my satisfaction about the treatment and results is"
I am totally satisfied with the treatment and results
I am not totally satisfied but would choose the same treatment again.
I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again.
I am dissatisfied with my treatment.
3 years after RT
Primary Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey
Participants indicate level of satisfaction by answering "my satisfaction about the treatment and results is"
I am totally satisfied with the treatment and results
I am not totally satisfied but would choose the same treatment again.
I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again.
I am dissatisfied with my treatment.
4 years after RT
Primary Percent of Participants Indicating Total Satisfaction or Not Totally Satisfied But Would Choose Same Treatment Again on Quality of Life (QOL) Survey Percent of participants indicating total satisfaction or not totally satisfied but would choose same treatment again on QOL survey
Participants indicate level of satisfaction by answering "my satisfaction about the treatment and results is"
I am totally satisfied with the treatment and results
I am not totally satisfied but would choose the same treatment again.
I am not totally satisfied and would choose the standard 5-6 week course of radiation if I had it to do all over again.
I am dissatisfied with my treatment.
5 years after RT
Primary Percent of Participants Experiencing Complications After Intervention Overall complication rate, as measured by percent of participants experiencing complications after intervention 1 month after RT
Primary Percent of Participants Experiencing Complications After Intervention Overall complication rate, as measured by percent of participants experiencing complications after intervention 3 month after RT
Primary Percent of Participants Experiencing Complications After Intervention Overall complication rate, as measured by percent of participants experiencing complications after intervention 6 month after RT
Primary Percent of Participants Experiencing Complications After Intervention Overall complication rate, as measured by percent of participants experiencing complications after intervention 9 month after RT
Primary Percent of Participants Experiencing Complications After Intervention Overall complication rate, as measured by percent of participants experiencing complications after intervention 12 month after RT
Primary Percent of Participants Experiencing Complications After Intervention Overall complication rate, as measured by percent of participants experiencing complications after intervention 2 years after RT
Primary Percent of Participants Experiencing Complications After Intervention Overall complication rate, as measured by percent of participants experiencing complications after intervention 3 years after RT
Primary Percent of Participants Experiencing Complications After Intervention Overall complication rate, as measured by percent of participants experiencing complications after intervention 4 years after RT
Primary Percent of Participants Experiencing Complications After Intervention Overall complication rate, as measured by percent of participants experiencing complications after intervention 5 years after RT
Secondary Percent of Participants With Delayed Wound Healing Wound healing rate, as measured by percent of participants with delayed wound healing 1 month after RT
Secondary Percent of Participants With Delayed Wound Healing Wound healing rate, as measured by percent of participants with delayed wound healing 3 month after RT
Secondary Percent of Participants With Delayed Wound Healing Wound healing rate, as measured by percent of participants with delayed wound healing 6 month after RT
Secondary Percent of Participants With Delayed Wound Healing Wound healing rate, as measured by percent of participants with delayed wound healing 9 month after RT
Secondary Percent of Participants With Delayed Wound Healing Wound healing rate, as measured by percent of participants with delayed wound healing 12 month after RT
Secondary Percent of Participants With Delayed Wound Healing Wound healing rate, as measured by percent of participants with delayed wound healing 2 years after RT
Secondary Percent of Participants With Delayed Wound Healing Wound healing rate, as measured by percent of participants with delayed wound healing 3 years after RT
Secondary Percent of Participants With Delayed Wound Healing Wound healing rate, as measured by percent of participants with delayed wound healing 4 years after RT
Secondary Percent of Participants With Delayed Wound Healing Wound healing rate, as measured by percent of participants with delayed wound healing 5 years after RT
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Recruiting NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A